BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 35655417)

  • 1. Lipids, Apolipoproteins, Statins, and Intracerebral Hemorrhage: A Mendelian Randomization Study.
    Yu Z; Zhang L; Zhang G; Xia K; Yang Q; Huang T; Fan D
    Ann Neurol; 2022 Sep; 92(3):390-399. PubMed ID: 35655417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of Lipids and Lipid-Lowering Drugs with Risk of Vascular Dementia: A Mendelian Randomization Study.
    Zhang X; Geng T; Li N; Wu L; Wang Y; Zheng D; Guo B; Wang B
    Nutrients; 2022 Dec; 15(1):. PubMed ID: 36615727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
    Liang Z; Zhao L; Lou Y; Liu S
    QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
    Tan Z; Hong J; Sun A; Ding M; Shen J
    Front Endocrinol (Lausanne); 2023; 14():1301163. PubMed ID: 38107516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis.
    Chen H; Zhou X; Hu J; Li S; Wang Z; Zhu T; Cheng H; Zhang G
    Lipids Health Dis; 2023 Dec; 22(1):220. PubMed ID: 38082436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study.
    Gormley M; Yarmolinsky J; Dudding T; Burrows K; Martin RM; Thomas S; Tyrrell J; Brennan P; Pring M; Boccia S; Olshan AF; Diergaarde B; Hung RJ; Liu G; Legge D; Tajara EH; Severino P; Lacko M; Ness AR; Davey Smith G; Vincent EE; Richmond RC
    PLoS Genet; 2021 Apr; 17(4):e1009525. PubMed ID: 33886544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.
    Xiao W; Li Y; Zhuang Z; Song Z; Wang W; Huang N; Dong X; Jia J; Liu Z; Zhao Y; Qi L; Huang T
    Lipids Health Dis; 2024 Jun; 23(1):163. PubMed ID: 38831433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of genetically predicted lipid traits and lipid-modifying targets with heart failure.
    Xiao J; Ji J; Zhang N; Yang X; Chen K; Chen L; Huang W
    Eur J Prev Cardiol; 2023 Mar; 30(4):358-366. PubMed ID: 36520639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
    Hong P; Han L; Wan Y
    Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.
    Yan Z; Xu Y; Li K; Liu L
    Acta Neurol Belg; 2024 Apr; 124(2):485-494. PubMed ID: 37889424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
    Bi Y; Zhu Y; Tang S; Huang Y
    J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.
    Qiao L; Lv S; Meng K; Yang J
    Clin Rheumatol; 2024 Mar; 43(3):939-947. PubMed ID: 38198113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage.
    Falcone GJ; Kirsch E; Acosta JN; Noche RB; Leasure A; Marini S; Chung J; Selim M; Meschia JF; Brown DL; Worrall BB; Tirschwell DL; Jagiella JM; Schmidt H; Jimenez-Conde J; Fernandez-Cadenas I; Lindgren A; Slowik A; Gill D; Holmes M; Phuah CL; Petersen NH; Matouk Md CN; Gunel M; Sansing L; Bennett D; Chen Z; Sun LL; Clarke R; Walters RG; Gill TM; Biffi A; Kathiresan S; Langefeld CD; Woo D; Rosand J; Sheth KN; Anderson CD;
    Ann Neurol; 2020 Jul; 88(1):56-66. PubMed ID: 32277781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    Lotta LA; Sharp SJ; Burgess S; Perry JRB; Stewart ID; Willems SM; Luan J; Ardanaz E; Arriola L; Balkau B; Boeing H; Deloukas P; Forouhi NG; Franks PW; Grioni S; Kaaks R; Key TJ; Navarro C; Nilsson PM; Overvad K; Palli D; Panico S; Quirós JR; Riboli E; Rolandsson O; Sacerdote C; Salamanca EC; Slimani N; Spijkerman AM; Tjonneland A; Tumino R; van der A DL; van der Schouw YT; McCarthy MI; Barroso I; O'Rahilly S; Savage DB; Sattar N; Langenberg C; Scott RA; Wareham NJ
    JAMA; 2016 Oct; 316(13):1383-1391. PubMed ID: 27701660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid traits and type 2 diabetes risk in African ancestry individuals: A Mendelian Randomization study.
    Soremekun O; Karhunen V; He Y; Rajasundaram S; Liu B; Gkatzionis A; Soremekun C; Udosen B; Musa H; Silva S; Kintu C; Mayanja R; Nakabuye M; Machipisa T; Mason A; Vujkovic M; Zuber V; Soliman M; Mugisha J; Nash O; Kaleebu P; Nyirenda M; Chikowore T; Nitsch D; Burgess S; Gill D; Fatumo S
    EBioMedicine; 2022 Apr; 78():103953. PubMed ID: 35325778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.
    Su Q; Wang R; Luo Y; Tang Q; Wang K
    Front Endocrinol (Lausanne); 2024; 15():1362499. PubMed ID: 38390206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
    Williams DM; Finan C; Schmidt AF; Burgess S; Hingorani AD
    Ann Neurol; 2020 Jan; 87(1):30-39. PubMed ID: 31714636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study.
    Tao H; Yu Z; Dong Y; Liu L; Peng L; Chen X
    Front Immunol; 2023; 14():1160312. PubMed ID: 37350960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between Genetically Proxied Inhibition of Lipid-Lowering Drug Targets and Serum Micronutrients among Individuals of European Descent: A Mendelian Randomization Study.
    He JY; Zhang X; Wang K; Lv WQ
    J Nutr; 2022 May; 152(5):1283-1290. PubMed ID: 35349717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.